drugset / Trial / NCT05769595

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

NCT05769595 ↗

Phase 1 Completed 17 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal disease (ESRD) on dialysis. There is no primary hypothesis for this study.

Timeline

Start
2023-06-14
Primary completion
2024-02-15
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2060 Monoclonal antibody 50 mg Intravenous